Nephropathic Cystinosis — A Gap between Developing and Developed Nations
- 3 April 2014
- journal article
- letter
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 370 (14), 1366-1367
- https://doi.org/10.1056/nejmc1309480
Abstract
Nephropathic cystinosis is a rare autosomal recessive lysosomal storage disease that, if untreated, leads to end-stage renal disease (ESRD) in the first decade of life because of intracellular accumulation of cystine caused by mutant cystinosin, the transporter of cystine.1,2 Since 1979, most patients in developed countries have received cysteamine, which enables the transport of cystine from cells and thus lowers the amount of intracellular cystine. Cysteamine has postponed ESRD and extrarenal manifestations until patients are in their teens or beyond.3,4 In contrast, patients in developing nations have remained largely untreated, mainly because of limited access to cysteamine.Keywords
This publication has 5 references indexed in Scilit:
- Long-term outcome of nephropathic cystinosis: a 20-year single-center experiencePediatric Nephrology, 2010
- Infantile nephropathic cystinosisKidney International, 2008
- Nephropathic cystinosis: late complications of a multisystemic diseasePediatric Nephrology, 2007
- CystinosisThe New England Journal of Medicine, 2002
- Improved Renal Function in Children with Cystinosis Treated with CysteamineThe New England Journal of Medicine, 1993